Sensorion, a biotechnology firm specializing in the development of therapies for the restoration, treatment and prevention of hearing disorders, has announced a reserved offer of €60 million.[1][2][3] The offer includes the issue of 214,285,714 new shares at a price of EUR 0.28 per share.[1][2] Investors include Sanofi with a €20 million investment, existing shareholders such as Redmile Group, Artal, Sofinnova Partners and others, including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare.[1][3] Net proceeds of approximately €56 million will be used to fund research and development of the SENS-501 and SENS-601 (GJB2-GT) gene therapies in equal shares, as well as other research and operating expenses.[1][2] The funding will support key milestones such as the approval of the SENS-601 clinical trial application for hearing loss caused by GJB2 mutations and the recruitment of the first clinical cohort.[1][3] The liquidity framework will be extended until the first half of 2027.[3] The offer is scheduled to be paid out around January 30, 2026, subject to the fulfillment of standard conditions.[1][2] Anticipated clinical milestones include 6-month follow-up data from the second cohort of the Audiogene study for SENS-501, Notoxis Phase 2a results for SENS-401, and the filing of the SENS-601 clinical trial in the first quarter of 2026.[1][4]